Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Salix Expects Acquisition Of Oceana, Two Products, To Be Quickly Accretive

This article was originally published in The Pink Sheet Daily

Executive Summary

Although privately held Oceana’s two products – Solesta and Deflux – are regulated by FDA as Class III medical devices, Salix intends to market them with existing sales forces.


Related Content

Device and Diagnostics Dealmaking Quarterly Statistics, Q4 2011
Start-Up Quarterly Statistics, Q4 2011
Amitiza Hits Mark In Confirmatory Opioid-Induced Bowel Dysfunction Study
GI Drugs Cmte. To Weigh Retreatment Study Design For Salix's Xifaxan In Irritable Bowel
Oceana To Launch Solesta For Fecal Incontinence By September
Progenics Finds New Partner For Relistor In Salix


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts